News

Published on 4 Jan 2023 on Benzinga via Yahoo Finance

Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV


Article preview image

Pulmatrix Inc (NASDAQ: PULM) completed the Phase 1 trial evaluating the safety and pharmacokinetics of PUR3100 in healthy volunteers.PUR3100 uses the company's iSPERSE formulation technology to create an orally inhaled dry powder dihydroergotamine (DHE) formulation for acute migraine.Twenty-six healthy subjects were enrolled, and each of the four groups contained at least six subjects.Related: Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results.PUR3100 was well-tolerated, and there was a lower incidence of nausea in PUR3100 dose groups compared to IV DHE.No emesis was observed in any of the PUR3100 dose groups. Oral inhalation of PUR3100 achieved peak exposures in the targeted therapeutic range at all doses, and the Tmax occurred at 5 minutes after dosing. Pulmatrix plans to present the data at an appropriate upcoming scientific conference.Dose selection is underway for the Phase 2 study, and an FDA meeting will be requested this month.The company plans to review the Phase 2 proof-of-concept study with the FDA in the first half of 2023.Price Action: PULM shares are down 14.32% at $3.65 on the last check Wednesday.

See more from Benzinga

NASDAQ.PULM price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Shares of Pulmatrix, Inc. (PULM) have been struggling lately and have lost 5.3% over the past two...

Zacks via Yahoo Finance 11 Sep 2023

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates

HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.22 per share versus the Zacks Con...

Zacks via Yahoo Finance 10 Aug 2023

Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV

Pulmatrix Inc (NASDAQ: PULM) completed the Phase 1 trial evaluating the safety and pharmacokineti...

Benzinga via Yahoo Finance 4 Jan 2023

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Conse...

Zacks via Yahoo Finance 5 May 2022

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse...

Here's a roundup of top developments in the biotech space over the last 24 hours. Lilly & Company...

Benzinga 25 Feb 2022

45 Stocks Moving In Friday's Mid-Day Session

Check out this: Insiders Sell Around $16M Of 4 Stocks Also check this out: Executives Buy Over $...

Benzinga 25 Feb 2022

32 Stocks Moving in Friday's Pre-Market Session By Benzinga

32 Stocks Moving in Friday's Pre-Market Session

Investing.com 25 Feb 2022

When Will Pulmatrix, Inc. (NASDAQ:PULM) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Pu...

Simply Wall St. via Yahoo Finance 2 Feb 2022

20 Stocks Moving in Tuesday's Pre-Market Session

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMar...

Benzinga 25 Jan 2022

Is TBLT Stock A Buy Here?

Most investors tend to think that hedge funds and other asset managers are worthless, as they can...

Insider Monkey via Yahoo Finance 7 Dec 2021